Wortzel 1975c.

Study characteristics
Methods	Trial design: randomised, double‐blind, multicentre, parallel study Trial registration number: not reported Country: USA (assumed from author affiliation) Outpatient or hospital: multiple outpatient centres Date trial conducted: not reported Duration of trial participation: 22 days Inclusion criteria: AD and psoriasis patients (data only extracted for AD patients) Exclusion criteria: not reported Additional design details: none
Participants	Total number randomised: 6 participants (2 to apply the intervention and 4 to apply the comparator) Age, sex, ethnicity, duration of eczema: not reported Severity of eczema: very severe; these patients had been hospitalised because of the severity of their condition. Body site, number of withdrawals: not reported Notes: none
Interventions	Run‐in details: not reported Intervention: betamethasone dipropionate 0.05% ointment used twice daily for 21 days · Concurrent treatment: not reported · Other key information: brand: Diprosone Comparator: vehicle ointment used twice daily for 21 days · Concurrent treatment: not reported · Other key information: brand: unspecified Concurrent treatments received alongside both intervention and comparator: not reported Notes: none
Outcomes	· Investigator's opinion of drug effects · Overall therapeutic response, assumed to be assessed by the physician: 5‐point scale (excellent, good, fair, poor, exacerbation) · AE
Notes	Funding source: test treatment was supplied by Schering Corporation, Bloomsfield, N. J. when it was not generally available. Declarations of interest: not declared apart from the above Original language of publication: English Other: none